Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Other Non-Current Liabilities (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Other Non-Current Liabilities data on record, last reported at $431000.0 in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 24.39% year-over-year to $431000.0; the TTM value through Dec 2025 reached $431000.0, down 24.39%, while the annual FY2025 figure was $431000.0, 24.39% down from the prior year.
  • Other Non-Current Liabilities reached $431000.0 in Q4 2025 per ARQT's latest filing, up from $360000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $849000.0 in Q4 2023 and bottomed at $12000.0 in Q2 2022.
  • Average Other Non-Current Liabilities over 5 years is $302846.2, with a median of $360000.0 recorded in 2025.
  • Peak YoY movement for Other Non-Current Liabilities: tumbled 72.57% in 2021, then soared 85.57% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $25000.0 in 2021, then plummeted by 52.0% to $12000.0 in 2022, then skyrocketed by 6975.0% to $849000.0 in 2023, then tumbled by 32.86% to $570000.0 in 2024, then fell by 24.39% to $431000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $431000.0 in Q4 2025, $360000.0 in Q3 2025, and $360000.0 in Q2 2025.